Brainstem Circuit Modulation for PSP

Overview

Overview

This experiment aims to develop and validate targeted brainstem circuit modulation strategies for Progressive Supranuclear Palsy (PSP), focusing on deep brain stimulation (DBS) and circuit-specific neuromodulation. PSP is characterized by prominent brainstem degeneration affecting the [pedunculopontine nucleus](/cell-types/ppn-cholinergic-psp), [locus coeruleus](/cell-types/locus-coeruleus-psp), and [substantia nigra](/cell-types/substantia-nigra-neurons-progressive-supranuclear-palsy), leading to the characteristic vertical gaze palsy, postural instability, and gait dysfunction.

Hypothesis

Primary Hypothesis: Targeted modulation of brainstem locomotor region circuits using adaptive deep brain stimulation will significantly improve gait and balance function in PSP patients.

Secondary Hypothesis: Combined DBS targeting of the [subthalamic nucleus](/cell-types/subthalamic-nucleus-psp) and pedunculopontine nucleus will provide synergistic benefits for motor and cognitive symptoms.

Background

PSP is associated with severe [brainstem circuit vulnerability](/mechanisms/brainstem-circuit-vulnerability-psp):

• Pedunculopontine Nucleus (PPN): Critical for gait initiation and postural control; degeneration correlates with falls
• Subthalamic Nucleus (STN): Involved in movement inhibition; hyperactive in PSP
• Locus Coeruleus: Noradrenergic center for arousal and attention
• Red Nucleus: Involved in motor coordination

• PPN-DBS: Promising for gait freezing but limited overall benefit
• STN-DBS: Mixed results, some worsening of cognitive symptoms
• Need for adaptive, closed-loop stimulation approaches

Detailed Protocol

Phase 1: Preclinical Validation (12 months)

• Animal Model: Transgenic 4R-[tau](/proteins/tau) mice with PPN degeneration
• Methods:
• Optogenetic PPN activation in tauopathy mice
• Behavioral assessment of gait and balance
• Electrophysiological recording of PPN-STN circuits
• Pharmacological validation (GABAergic and cholinergic agents)

Phase 2: Computational Modeling (6 months)

• Develop patient-specific computational models of brainstem circuits
• Validate targeting coordinates using [diffusion tensor imaging](/biomarkers/dti-white-matter-cbs-psp)
• Simulation of adaptive stimulation parameters

Phase 3: Clinical Trial (18 months)

• Design: Randomized, sham-controlled, double-blind
• Subjects: 60 patients with PSP-Richardson syndrome, age 50-75, H&Y stage 2.5-4.0
• Groups:
• Adaptive PPN-DBS (n=20)
• Standard PPN-DBS (n=20)
• Sham stimulation (n=20)
• Primary Endpoint: Change in PSP Rating Scale (PSPRS) total score at 12 months

Outcome Measures

• Primary:
• PSP Rating Scale (PSPRS) total score
• Gait velocity (10-meter walk test)
• Fall frequency (prospective diary)
• Secondary:
• [Vertical gaze function](/mechanisms/psp-ocular-motor-dysfunction) (video oculography)
• Cognitive function (MDS-UPDRS Part I, Frontal Assessment Battery)
• Quality of life (PSP-QoL)
• Brain imaging (MRI volumetry, DTI connectivity)
• CSF biomarkers ([neurofilament light chain](/biomarkers/cbs-psp-csf-biomarkers))

Reagents and Equipment

| Item | Supplier | Cost (USD) |
|------|----------|-------------|
| DBS electrodes (directed leads) | Boston Scientific | $180,000 |
| Implantable pulse generator | Boston Scientific | $120,000 |
| Adaptive stimulation software | Custom | $80,000 |
| Video oculography system | SR Research | $45,000 |
| Gait analysis system (instrumented walkway) | GAITRite | $25,000 |
| 3T MRI time | University hospital | $60,000 |
| CSF sampling kits | Lumbar puncture | $15,000 |
| Neuropsychological testing batteries | Standardized | $10,000 |
| Bioinformatics analysis | In-house | $30,000 |

Estimated Total Cost: $565,000 (clinical phase only)

Suggested Laboratories

Timeline

• Months 1-12: Preclinical validation in animal models
• Months 8-14: Computational modeling and surgical planning
• Months 15-32: Clinical trial recruitment and implantation
• Months 33-44: Follow-up and data collection
• Months 45-48: Data analysis and publication

Expected Outcomes

Primary Endpoints

• ≥3-point improvement in PSPRS total score in adaptive DBS group vs sham
• 25% improvement in gait velocity
• 40% reduction in fall frequency

Secondary Endpoints

• Significant improvement in vertical gaze metrics
• Stabilization of cognitive function
• Identification of biomarkers predicting DBS response

Risk Mitigation

• Strict inclusion/exclusion criteria (exclude severe cognitive impairment)
• Independent data safety monitoring board
• Pre-specified stopping rules for futility or harm

Scoring

| Dimension | Score (1-10) | Rationale |
|-----------|--------------|-----------|
| Scientific Value | 9 | Novel adaptive DBS approach for brainstem circuits |
| Feasibility | 6 | Requires specialized surgical expertise, multi-site coordination |
| Novelty | 9 | First adaptive DBS trial specifically for PSP brainstem circuits |
| Disease Impact | 10 | Addresses disabling gait/fall symptoms with no current treatment |
| Reach | 8 | Would benefit ~50,000 US PSP patients with gait dysfunction |
| Cost Efficiency | 5 | High cost but potentially transformative |
| Time Efficiency | 5 | 48-month timeline is lengthy |
| Evidence Base | 7 | Preclinical data supports PPN modulation, limited clinical data |
| Addresses Uncertainty | 8 | Tests whether adaptive DBS outperforms standard approaches |
| Translation Potential | 10 | Direct path to clinical implementation if successful |

Total Score: 77 × weight normalization = ~110/140

Related Pages

• [Brainstem Circuit Vulnerability in PSP](/mechanisms/brainstem-circuit-vulnerability-psp)
• [Pedunculopontine Nucleus Cholinergic in PSP](/cell-types/ppn-cholinergic-psp)
• [Subthalamic Nucleus Neurons in PSP](/cell-types/subthalamic-nucleus-psp)
• [PSP Clinical Trials](/clinical-trials/progressive-supranuclear-palsy)
• [Gait and Balance Disorders in PSP](/mechanisms/psp-gait-balance-disorders)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/)
• [Movement Disorders Society](https://www.movementdisorders.org/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Brainstem Circuit Modulation for PSP discovered through SciDEX knowledge graph analysis: